| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Remikiren is an orally active, high specificity renin inhibitor. |
| Indication |
For the treatment of hypertension and heart failure |
| Pharmacology |
Remikiren is an orally available renin inhibitor with an established blood pressure-lowering effect in patients with essential hypertension. No data are available on the renal effects of remikiren in humans. In patients with essential hypertension, a single oral dose of remikiren can induce a renal vasodilation, without affecting the GFR and despite a significant decrease in blood pressure. This systemic and renal hemodynamic response is more pronounced in case of a more activated renin-angiotensin system. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Absorption |
Absorbed following oral administration. |
| Protein Binding |
83% |
| References |
| • |
Clozel JP, Fischli W: Discovery of remikiren as the first orally active renin inhibitor. Arzneimittelforschung. 1993 Feb;43(2A):260-2.
[Pubmed]
|
| • |
Richter WF, Whitby BR, Chou RC: Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals. Xenobiotica. 1996 Mar;26(3):243-54.
[Pubmed]
|
|
| External Links |
|